Metformin does not improve survival in unselected patients with metastatic hormone-sensitive prostate cancer (mHSPC), but the drug may improve survival and other outcomes in those with high-volume ...
Incidence of death or postacute sequelae of SARS-CoV-2 slightly lower with prevalent metformin use. HealthDay News — After SARS-CoV-2 infection, prevalent metformin use is associated with a ...